Menu Search
Equities

Arbutus Biopharma Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
I9DN:DUS

Arbutus Biopharma Corp

Actions
  • Price (EUR)3.17
  • Today's Change0.02 / 0.63%
  • Shares traded750.00
  • 1 Year change-6.43%
  • Beta0.7444
Data delayed at least 15 minutes, as of Feb 06 2026 18:32 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

  • Revenue in USD (TTM)14.61m
  • Net income in USD-42.28m
  • Incorporated2017
  • Employees44.00
  • Location
    Arbutus Biopharma Corp701 Veterans CircleWARMINSTER 18974United StatesUSA
  • Phone+1 (267) 469-0914
  • Fax+1 (604) 419-3201
  • Websitehttps://www.arbutusbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.